Troubled drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the combined companies. Post-merger, the company will be listed on the New York Stock Exchange and is projected to generate around $3.6 billion in revenue this year.
Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...
Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts said.
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...
Three Democratic senators want answers from Health and Human Services Secretary Robert F. Kennedy Jr. about his private meetings with drugmakers alongside President Trump at his Mar-a-Lago club in ...
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback